Best Neurology Companies in Maryland, United States
The 47 best Neurology companies in Maryland, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Regenxbio.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Maryland
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Regenxbio Developer of AAV Gene Therapy for rare genetic diseases | $108M | 71 mo ago | 344 344 → 389 (+13%) | — | DrupalPHPAmazon Web Services+17 | Top 5M | 490 patents AAV vector manufacturing and glycosylated enzyme gene‑therapy delivery | 1 award |
| 2 | eNeura Developer of a transcranial magnetic stimulation device for pain relief | $71M | 78 mo ago | 17 | — | WordPressMySQLPHP+20 | Top 50M | 21 patents Non‑invasive brain stimulation therapies for migraine and neuropathic pain | — |
| 3 | BrainScope Provider of AI-powered non-invasive medical devices for diagnosing and assessing brain injuries, including… | $62M | 34 mo ago | 38 38 → 34 (-11%) | Michael Singer Co-CEO | HubSpot CMS HubEnvoyBootstrap+15 | Top 50M | 165 patents Non‑invasive EEG/brain‑monitoring systems for concussion diagnosis and neuro‑assessment | — |
| 4 | OncoC4 Developer of immunotherapy for cancer patients 62Patents top 17%Innovation top 21%Funding top 28%Moat top 33% All 7 signals ▾Patentstop 17% Innovationtop 21% Fundingtop 28% Moattop 33% Globalbottom 43% Marketbottom 42% Newsbottom 34% Patents: 128 patents matched (strict assignee match) · 115 filings since 2022 vs 13 in 2017-21 Innovation: 128 patents (top 15% of patent-holders) · 115 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $52M | 10 mo ago | 41 | — | — | — | 128 patents Immune checkpoint antibody therapeutics targeting CTLA‑4 and CD80/86 for cancer. | 1 job opening |
| 5 | Cerecor Developer of therapeutics for Immunological disorders and neurological disorders | $45M | 111 mo ago | 20 20 → 49 (+145%) | — | — | — | 50 patents Developing nucleic acid prodrugs and small‑molecule therapeutics for cardiovascular and metabolic diseases | 8 job openings |
| 6 | CraniUS A medical technology company developing drug delivery systems to treat brain diseases and disorders 64Patents top 23%Innovation top 28%Funding top 31%Moat top 34% All 7 signals ▾Patentstop 23% Innovationtop 28% Fundingtop 31% Moattop 34% Talenttop 38% Globaltop 48% Marketbottom 49% Patents: 47 patents matched (strict assignee match) · 47 filings since 2022 vs 0 in 2017-21 Innovation: 47 patents (top 32% of patent-holders) · 47 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $42M | 6 mo ago | — | Chad Gordon Founder & CMO | — | — | 47 patents Smart implantable devices and flexible catheters for drug delivery and wireless power | — |
| 7 | Neuraly Pioneering neurodegenerative disease treatments, offering hope for Alzheimer's and Parkinson's | $36M | 96 mo ago | 42 | Seulki Lee Co-Founder & CEO | Cart FunctionalitySquarespace CommerceSquarespace+16 | Top 50M | 9 patents Therapeutic peptide and small‑molecule drugs targeting GLP‑1, TRAIL and soluble epoxide hydrolase. | — |
| 8 | Supernus Pharmaceuticals Innovating CNS treatments, improving lives through neurological and psychiatric solutions | $30M | 145 mo ago | 652 652 → 845 (+30%) | Jack Khattar President & CEO | DrupalPHPAmazon Web Services+24 | Top 5M | 403 patents Novel CNS therapeutic small molecules and modified-release formulations for neurological disorders | — |
| 9 | Antidote Therapeutics Developing nicotine-blockers to treat diseases caused by nicotine and addiction | $22M | 15 mo ago | 3 | Matthew Kalnik Founder & CEO | — | — | — | — |
| 10 | CraniUS Developer of drug delivery device for brain diseases | $20M | 25 mo ago | 25 | Chad Gordon Co-Founder & CMO | — | — | 47 patents Patents concentrated in electrical & electronics | 1 award |
| 11 | Longeviti Developer of implantable neurosurgical devices | $17M | 19 mo ago | 18 | — | — | — | — | 1 launch · 1 award |
| 12 | Impulse Monitoring Intraoperative neurophysiological monitoring | $14M | 233 mo ago | 150 | Patrick Miles CEO | — | — | 4 patents Real-time intraoperative neurophysiological monitoring data integration and positioning effect analysis | — |
| 13 | Valted Seq Developer of therapeutic solutions and biomarkers for treating neurodegenerative diseases | $12M | 57 mo ago | 6 | Valina Dawson Co-Founder | — | — | — | — |
| 14 | AgeneBio Therapeutic to treat amnestic mild cognitive impairment (aMCI) due to Alzheimer’s disease. | $12M | 10 mo ago | 1 | — | WordPressMySQLPHP+9 | Top 50M | 203 patents Neuropharmacology: benzodiazepine and levetiracetam formulations for cognitive disorder therapy | — |
| 15 | RightEye Provider of eye-tracking solution for general healthcare and wellness | $11M | 77 mo ago | 14 | — | WordPress Block EditorWordPressMySQL+33 | Top 10M | 34 patents Eye‑tracking based physiological monitoring and vision performance assessment platforms | — |
| 16 | Creative Bio-Peptides Developer of oral peptide treatments for neurodegenerative diseases | $11M | 14 mo ago | — | Michael Ruff Founder & CEO | — | — | — | — |
| 17 | SafeOp Revolutionizing spine surgery with innovative solutions and advanced approach technologies | $11M | 102 mo ago | 15 | — | — | — | 2 patents Neurophysiological monitoring and automated electrode positioning detection for evoked potentials | — |
| 18 | Arcion Therapeutics Developed innovative topical treatments to provide pain relief | $11M | 166 mo ago | — | James N. Campbell CEO | — | — | — | — |
| 19 | SYNAPS Dx Developer of a diagnostic test to detect Alzheimer's disease | $10M | 53 mo ago | 22 | Frank Amato CEO & President | WebflowGSAPSwiper+14 | Top 50M | 2 patents Secure attachment mechanisms for cochlear implant external transmitters | — |
| 20 | Flavocure Biotech Developing next-generation oncology solutions inspired by nature for cancer treatment | $8M | 18 mo ago | — | Henry Lowe Co-Founder | — | — | — | — |
| 21 | Adlyfe Develops biomarkers and diagnostic tests for amyloid diseases | $8M | 161 mo ago | 1 | Richard Cliff CEO | — | — | 79 patents Peptide-based probes for amyloid detection and freeze‑dried platelet therapeutics | — |
| 22 | Psyadon Pharmaceuticals Provides safe, minimally invasive penis enlargement with hyaluronic acid injections | $8M | 213 mo ago | 1 | — | — | — | — | — |
| 23 | Brain Biosciences Secure Google Account access, management, and language localization services | $6M | 131 mo ago | 4 | David Beylin CEO | — | — | — | — |
| 24 | DioGenix Next generation sequencing tests for multiple sclerosis. | $5M | 152 mo ago | — | — | Microsoft ASP.NETcore-jsSlick+11 | Top 50k | — | — |
| 25 | NeuroCytonix Developer of medical devices for the treatment of neurodegenerative diseases | $4M | 40 mo ago | 5 | — | Craft CMSApple iCloud MailMicrosoft 365+10 | Top 5M | — | — |
| 26 | Cellicure Developer of cell-based immunotherapies for cancer treatment | $4M | 51 mo ago | 3 | Q Li Co-Founder & CEO | — | — | 6 patents Genetically engineered immune cell therapies (e.g., CAR‑T, modified lymphocytes) | — |
| 27 | Seneca Biopharma Provider of therapeutics for neurological disease | $3M | 78 mo ago | 12 | — | — | — | — | — |
| 28 | Primetime Life Sciences Developer of translational medicine | $3M | 83 mo ago | — | Janak Padia President & CEO | — | — | — | — |
| 29 | Solaxa Developer of therapeutics for rare neurodegenerative disease and acute nerve injuries | $2M | 24 mo ago | — | Christian Walker Founder & CEO | WordPressMySQLPHP+7 | Top 50M | — | — |
| 30 | Diagnostic Biochips Developer of diagnostic biosensors for continuous monitoring | $1M | 65 mo ago | 7 | Greg Alden Chief Executive Officer | — | — | — | — |
| 31 | NeuroNascent Developing neuron regenerative therapies for neurological disorders, improving patient well-being | $1M | 95 mo ago | 3 | — | — | — | 67 patents Lipid-based delivery formulations for heterocyclic small‑molecule therapeutics | — |
| 32 | Polaris Genomics Developer genomic-based diagnostics and therapeutics for neurological conditions | $800K | 11 mo ago | 10 | Tshaka Cunningham Co-Founder | — | — | — | — |
| 33 | BSD Developer of multigenic therapies for complex diseases | $705K | 5 mo ago | 7 | Thomas Reed Founder & CEO | — | — | — | — |
| 34 | Cogentis Therapeutics Developer of therapeutics that prevent neurodegeneration and restore brain function | $497K | 15 mo ago | 154 | Kent Werner Co-Founder & CEO | — | — | — | — |
| 35 | TeraImmune Developer of cell therapies for treating different diseases | $225K | 100 mo ago | 10 | Jihoon Park Co-Founder & COO | — | — | 11 patents Cellular immunotherapy using cord‑blood‑derived regulatory T cells and enhanced stem‑cell combos for dermatitis | — |
| 36 | SpringWear Developer of wearable robotic devices for hand rehabilitation after stroke | $100K | 16 mo ago | — | Rafael Casas Founder & CEO | — | — | — | — |
Top 12 Neurology companies in Maryland
#1
Series B · Baltimore, Maryland · founded 2021$41.5Mraised▾
A medical technology company developing drug delivery systems to treat brain diseases and disorders. It is a technology company that develops implantable devices for brain tumor treatment. Its flagship product, NeuroPASS, is a drug delivery system designed to bypass the blood-brain barrier using precise flow rate of medication directly to the brain for the treatment of aggressive brain tumors, Alzheimer’s, and Parkinson’s disease.
- Jan 2026Grant (prize money)$1M
- Jan 2026Series B$19M
- Jun 2024Grant (prize money)$1M
- Sep 2022Series A$20M
#2
Series B · Rockville, Maryland · founded 2020 · 41 employees$52.3Mraised▾
Developer of immunotherapy for cancer patients. The lead product, CD24Fc reduces disease progression to death or respiratory failure. The lead candidate ONC-392 is a next-generation anti-CTLA-4 antibody, other candidates targeting cancer cells through chimeric antigen receptors T cells, bi-specific antibodies, and antibody-drug conjugates cells.
- Oct 2025Series B$50M
- Apr 2020Grant (prize money)$2.3M
#3
Series A · Baltimore, Maryland · founded 2008 · 1 employees$11.5Mraised▾
AgeneBio is developing therapeutics that prevent neurodegeneration and preserve & restore cognitive function for patients battling aMCI (pre-dementia stage of Alzheimer's), & other neurological and psychiatric diseases. AgeneBio’s Phase 3-ready lead candidate, AGB101, is targeting brain network imbalance and intend to treat aMCI & delay progression to Alzheimer’s dementia. Also has a small molecule discovery program to attenuate & control hippocampal overactivity with therapeutic potential for conditions including aMCI, autism, and schizophrenia.
- Sep 2025Grant (prize money)$23.5M
- May 2025Grant (prize money)$4.9M
- Apr 2025Grant (prize money)$4.9M
- Sep 2019Grant (prize money)$500K
#4
Funding Raised · Gaithersburg, Maryland · founded 2017 · 3 employees$22.4Mraised▾
Developing nicotine-blockers to treat diseases caused by nicotine and addiction. The company is focused on creating first-in-class treatments targeting rare vascular diseases and addiction through proprietary treatments. They leverage a global collaborative drug research and development network, incorporating expertise from academic labs, clinical research groups, biotechnology companies, and biopharmaceutical consultants. Their pipeline includes a fully human, anti-nicotine monoclonal antibody and a nicotine-degrading enzyme, both in development. The company aims to address the global health crisis related to smoking by providing innovative therapeutic solutions. This involves immunotherapeutic approaches, clinical research, and biopharmaceutical drug development.
- Apr 2025Grant (prize money)$13.1M
- Sep 2017Grant (prize money)$8.5M
- Sep 2017Conventional Debt$200K
- Aug 2017Conventional Debt$432.3K
#5
Funding Raised · Rockville, Maryland · founded 2017$10.9Mraised▾
Developer of oral peptide treatments for neurodegenerative diseases. The company's proprietary platform is developing novel oral peptide immunotherapies for neurodegeneration, brain injuries, and chronic pain. It has developed chemokine receptor antagonist (CCR2/CCR5) peptides to block neuroinflammation and also delivers oral, brain penetrant small peptides that modulate innate immunity to reduce inflammation, lower cytokines, and neuroregeneration. The company is developing Dala1-peptide T-amide for Neuro-AIDS.
- May 2025Grant (prize money)$2.5M
- Sep 2023Grant (prize money)$499.9K
- Sep 2021Grant (prize money)$4.9M
- Sep 2020Grant (prize money)$449.2K
#6
Seed · Frederick, Maryland · founded 2020 · 7 employees$705Kraised▾
Developer of multigenic therapies for complex diseases. The company uses proprietary purpose-built multigenic technology platforms to create MSC derived therapies for cardiovascular, neurodegenerative, and musculoskeletal diseases.
- Mar 2026Seed$705K
#7
Series B · Hunt Valley, Maryland · founded 2014 · 18 employees$17Mraised▾
Developer of implantable neurosurgical devices. Its product, ClearFit is a neurosurgical implant (implantable prosthetic plate) which corrects and restores bony voids or defects of the cranium. It helps neurosurgeons to see neuroanatomy and critical functional components beneath once implanted in the brain.
- Dec 2024Series B$1.2M
- Oct 2023Series A$750K
- May 2023Series A$1.2M
- Aug 2020Series A$5.5M
#8
Series A · Baltimore, Maryland · founded 2014$8.4Mraised▾
Developing next-generation oncology solutions inspired by nature for cancer treatment. The company focuses on transforming natural products into innovative cures for patients, particularly in oncology. They are discovering and advancing promising drug candidates through clinical research, targeting driver mutations implicated in cancer. Their lead drug candidate has received FDA Orphan Drug Designation for pancreatic cancer, and their research extends to other cancers like Glioblastoma, Acute Myeloid Leukemia, and Multiple Myeloma. The company collaborates with research institutions to develop new therapeutics for cancer treatment. They are exploring partnering opportunities with pharmaceutical and biotechnology companies to expand into various therapeutic areas. The company is dedicated to addressing unmet needs in cancer care through innovative, nature-inspired solutions.
- Feb 2025Series A$215K
- Jan 2023Series A$1.1M
- Sep 2019Series A$1.5M
- Nov 2018Series A$5.8M
#9
Series A · Rockville, Maryland · founded 2017 · 10 employees$800Kraised▾
Developer genomic-based diagnostics and therapeutics for neurological conditions. The company uses a proprietary bioinformatics engine TruNorth Platform for Neuropsychiatric genomic analysis. Also, it develops PTS-ID a genomic test for the diagnosis and treatment of Post-traumatic stress disorder.
- Aug 2025Conventional Debt$250K
- Oct 2023Conventional Debt$1M
- May 2023Conventional Debt$1M
- Feb 2021Conventional Debt$100K
#10
Series B · Bethesda, Maryland · founded 2006 · 38 employees$62.2Mraised▾
Provider of AI-powered non-invasive medical devices for diagnosing and assessing brain injuries, including concussions and brain bleeds.
- Sep 2023Series B—
- Oct 2021Series B—
- Aug 2017Series B$16.4M
- Sep 2015Series B$2.5M
#11
Series A · Baltimore, Maryland · founded 2021 · 25 employees$20.5Mraised▾
Developer of a medical device designed to redefine various diagnostics and treatments for neurosurgical patients with brain disease. The company's device offers a novel wireless charging system for neurosurgical patients that helps to deliver medicine directly to the brain, enabling healthcare organizations to access necessary technology for the treatment of brain disease.
#12
Seed · Baltimore, Maryland · founded 2015 · 154 employees$497.1Kraised▾
Developer of therapeutics that prevent neurodegeneration and restore brain function. The company is focused on a novel molecular target, cyclin-dependent kinase 5 (CDK5) that is hyperactivated in brains with frontotemporal dementia (FTD), Alzheimer’s (AD) as well as other tauopathies and plays a key role in disease progression. The company's lead compound, CT-526 is a peptide that inhibits abnormal CDK5 activity.
- Apr 2025Grant (prize money)$2.1M
- Sep 2021Grant (prize money)$2.2M
- Sep 2018Grant (prize money)$733.1K
- 2018Seed$497.1K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
How research on Neurotech in Maryland is moving
A read on the academic research around Neurotech in Maryland — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 45 papers.
- University of Maryland, Baltimore31
- University of Maryland, College Park11
- University of Maryland Medical Center6
- University of Maryland, Baltimore County4
- Maryland Oncology Hematology1
- Neuroscience5
- Neurostimulation4
- Sensory system2
- Chronic pain2
- Stimulation2
- Thalamotomy1→3
- Stimulation1→3
- Deep brain stimulation2→3
- Neuroscience2→3
- Neurostimulation5
- Deep brain stimulation4
- Epilepsy3
- Neuroprosthetics2
- Brain–computer interface2
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.